Animal models of the non-motor features of Parkinson's disease

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 597-606

  McDowell, Kimberly ^a   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mice; Non human primates; Rats

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALCOHOL DEHYDROGENASE; ALCOHOL DEHYDROGENASE 4; DOPAMINE; LEVODOPA; NICOTINE; NICOTINIC AGENT; OXIDOPAMINE; PARAQUAT; PESTICIDE; ROTENONE; TRANSCRIPTION FACTOR PITX3; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANXIETY; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GASTROINTESTINAL DISEASE; GENETIC MODEL; GENETIC RISK; HUMAN; MOUSE MUTANT; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REM SLEEP; REVIEW; SENSORY DYSFUNCTION; SLEEP DISORDER; SLOW WAVE SLEEP; SMELLING DISORDER; TRANSGENIC MOUSE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYDOPAMINES; MPTP POISONING; NEUROTOXINS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RISK FACTORS; ROTENONE; UNCOUPLING AGENTS;

EID: 84859699540     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.040     Document Type: Review

References (178)

1. Abbott R.D., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
2. Abbott R.D., et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord. 2007, 22:1581-1586.
3. Almirall H., et al. Nocturnal sleep structure and temperature slope in MPTP treated monkeys. J. Neural Transm. 1999, 106:1125-1134.
4. Anderson G., et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 2007, 207:4-12.
5. Ardayfio P., et al. Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol. Dis. 2008, 31:406-412.
6. Arman A., et al. Association between sporadic Parkinson disease and interleukin-1 beta-511 gene polymorphisms in the Turkish population. Eur. Cytokine Netw. 2010, 21:116-121.
7. Barraud Q., et al. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp. Neurol. 2009, 219:574-582.
8. Bassetti C.L. Nonmotor disturbances in Parkinson's disease. Neurodegener. Dis. 2011, 8:95-108.
9. Belin A.C., et al. Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice. Behav. Brain Res. 2011, 217:439-445.
10. Bergman O., et al. PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiol. Aging 2010, 31:114-117.
11. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
12. Bibbiani F., et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 2005, 192:73-78.
13. Boeve B.F., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
14. Bonifati V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
15. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
16. Braak H., et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72.
17. Breese G.R., Traylor T.D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol. 1971, 42:88-99.
18. Bronstein J.M., et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch. Neurol. 2011, 68:165.
19. Brown T.P., et al. Pesticides and Parkinson's disease-is there a link?. Environ. Health Perspect. 2006, 114:156-164.
20. Cannon J.R., et al. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
21. Carlsson A. Biochemical and pharmacological aspects of parkinsonism. Acta Neurol. Scand. Suppl. 1972, 51:11-42.
22. Carlsson A., et al. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
23. Caudle W.M., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27:8138-8148.
24. Chandran J.S., et al. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol. Dis. 2008, 29:505-514.
25. Chaudhuri K.R., et al. Parkinson's Disease: The Non-Motor Issues 2011, Parkinsonism Relat Disord.
26. Chaumette T., et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 2009, 21:215-222.
27. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 1996, 19:417-422.
28. Chudler E.H., Lu Y. Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine. Brain Res. 2008, 1213:41-47.
29. Cools R., et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 2001, 11:1136-1143.
30. Cools R., et al. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007, 32:180-189.
31. Da Cunha C., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav. Brain Res. 2001, 124:9-18.
32. Decamp E., Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur. J. Neurosci. 2004, 20:1371-1378.
33. Decamp E., Schneider J.S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res. 2009, 1262:109-114.
34. Dickson D.W., et al. Evidence in favor of Braak staging of Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S78-S82.
35. Djaldetti R., et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004, 62:2171-2175.
36. Dluzen D.E. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces norepinephrine concentrations in the olfactory bulbs of male mice. Brain Res. 1992, 586:144-147.
37. Dorsey E.R., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
38. Doty R.L., et al. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann. Neurol. 1992, 32:97-100.
39. Drolet R.E., et al. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36:96-102.
40. Edwards L.L., et al. Gastrointestinal symptoms in Parkinson's disease. Mov. Disord. 1991, 6:151-156.
41. Factor S.A. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 2008, 5:164-180.
42. Fahn S., P.S. Parkinsonism 2010, 751-769. Lippincott Williams & Wilkins, New York. P.T. Rowland LP (Ed.).
43. Faull R.L., Laverty R. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp. Neurol. 1969, 23:332-340.
44. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt. 5):2283-2301.
45. Feger J., et al. Experimental models of Parkinson's disease. Ann. Pharm. Fr. 2002, 60:3-21.
46. Fernagut P.O., et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007, 61:991-1001.
47. Fernandez-Ruiz J., et al. Long-term cognitive impairment in MPTP-treated rhesus monkeys. Neuroreport 1995, 7:102-104.
48. Ferrante R.J., et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 1997, 753:157-162.
49. Ferro M.M., et al. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 2005, 148:78-87.
50. Fleming S.M., et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 2004, 24:9434-9440.
51. Fleming S.M., et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 2004, 187:418-429.
52. Fleming S.M., et al. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 2006, 142:1245-1253.
53. Fleming S.M., et al. Impaired reversal learning in transgenic mice overexpressing human wildtype alpha-synuclein. Soc. Neurosci. Abstr. 2008, 341.1:N3.
54. Fleming S.M., et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
55. Fleming S.M., et al. Alterations in heart rate variability in transgenic mice overexpressing human wildtype alpha synuclein. Soc. Neurosci. Abstr. 2009, 531.9:K8.
56. Freichel C., et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 2007, 28:1421-1435.
57. Fuchs J., et al. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol. Aging 2009, 30:731-738.
58. George S., et al. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp. Neurol. 2008, 210:788-792.
59. Gerlach M., et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics 2011, J. Neural Transm.
60. Gevaerd M.S., et al. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res. Bull. 2001, 55:101-106.
61. Glatt C.E., et al. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum. Mol. Genet. 2006, 15:299-305.
62. Goldberg M.S., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278:43628-43635.
63. Goldberg M.S., et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
64. Goldstein D.S., et al. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003, 306:855-860.
65. Gonera E.G., et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov. Disord. 1997, 12:871-876.
66. Gravotta L., et al. Global Depletion of Dopamine Using Intracerebroventricular 6-Hydroxydopamine Injection Disrupts Normal Circadian Wheel-Running Patterns and PERIOD2 Expression in the Rat Forebrain. J. Mol. Neurosci. 2011, 45 (2):162-171.
67. Greene J.G., et al. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 2009, 218:154-161.
68. Guillot T.S., Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 2009, 39:149-170.
69. Ha A.D., et al. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat. Disord. 2011, 17:625-628.
70. Halliday G.M., et al. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 1990, 510:104-107.
71. Halliday G., et al. Milestones in Parkinson's disease-clinical and pathologic features. Mov. Disord. 2011, 26:1015-1021.
72. Harding A.J., et al. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002, 125:2431-2445.
73. Hawkes C.H., et al. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:79-84.
74. Hwang D.Y., et al. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 2003, 114:123-131.
75. Hwang D.Y., et al. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 2005, 25:2132-2137.
76. Iranzo A., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006, 5:572-577.
77. Javitch J.A., et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:2173-2177.
78. Jellinger K.A. Formation and development of Lewy pathology: a critical update. J. Neurol. 2009, 256(Suppl. 3):270-279.
79. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S26-S36. (discussion S36-8).
80. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann. Neurol. 2008, 64(Suppl. 2):S16-S29.
81. Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S18-S23.
82. Johnson R.E., et al. Akinesia and postural abnormality after unilateral dopamine depletion. Behav. Brain Res. 1999, 104:189-196.
83. Kano O., et al. Neurobiology of depression and anxiety in Parkinson's disease. Parkinsons Dis. 2011, 2011:143547.
84. Kaur H., et al. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease. Neurochem. Res. 2011, 36:1435-1443.
85. Kehagia A.A., et al. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9:1200-1213.
86. Kim R.H., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5215-5220.
87. Kingsbury A.E., et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord. 2010, 25:2508-2515.
88. Kruger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
89. Kudo T., et al. Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 2011, 232:66-75.
90. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000, 16:365-379.
91. Kuo Y.M., et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
92. Laloux C., et al. MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp. Brain Res. 2008, 186:635-642.
93. Lam H.A., et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 2011, 89:1091-1102.
94. Langston J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46:598-605.
95. Lawal H.O., et al. The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiol. Dis. 2010, 40:102-112.
96. Le W., et al. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol. Aging 2011, 32:750-753.
97. Lim S.Y., et al. Overview of the extranigral aspects of Parkinson disease. Arch. Neurol. 2009, 66:167-172.
98. Lim Y., et al. Alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 2011, 31:10076-10087.
99. Lima M.M., et al. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS One 2007, 2:e513.
100. Litteljohn D., et al. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur. J. Neurosci. 2008, 28:707-716.
101. Lucking C.B., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 2000, 342:1560-1567.
102. Magen I., Chesselet M.F. Genetic mouse models of Parkinson's disease: the state of the art. Prog. Brain Res. 2010, 184:53-87.
103. Manning-Bog A.B., et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277:1641-1644.
104. Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J. Neurol. Sci. 2011.
105. Masliah E., et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6:e19338.
106. McCormack A.L., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10:119-127.
107. McDowell K.A., et al. Sleep alterations in an environmental neurotoxin-induced model of parkinsonism. Exp. Neurol. 2010, 226:84-89.
108. Menza M., et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
109. Miller G.W., et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 1999, 156:138-148.
110. Monaca C., et al. Vigilance states in a parkinsonian model, the MPTP mouse. Eur. J. Neurosci. 2004, 20:2474-2478.
111. Mulligan C.K., et al. Mice overexpressing human wildtype alpha-synuclein under the Thy-1 promoter exhibit anomalies in behavioral tests of anxiety. Soc. Neurosci. Abstr. 2008, 742.19:U28.
112. Nicklas W.J., et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985, 36:2503-2508.
113. Nuber S., et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J. Neurosci. 2008, 28:2471-2484.
114. Nunes I., et al. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4245-4250.
115. Oka H., et al. Characteristics of orthostatic hypotension in Parkinson's disease. Brain 2007, 130:2425-2432.
116. Padovani A., et al. Parkinson's disease and dementia. Neurol. Sci. 2006, 27(Suppl. 1):S40-S43.
117. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1991, 50:743-755.
118. Pedersen K.M., et al. No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov. Disord. 2005, 20:164-171.
119. Perese D.A., et al. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 1989, 494:285-293.
120. Perl D.P. The neuropathology of parkinsonism. Handb. Clin. Neurol. 2007, 83:205-215.
121. Pham T.T., et al. DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav. 2010, 9:305-317.
122. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
123. Prediger R.D., et al. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp. Neurol. 2006, 202:391-403.
124. Prediger R.D., et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox. Res. 2010, 17:114-129.
125. Przedborski S., et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
126. Rabinovic A.D., et al. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 2000, 101:67-76.
127. Rajput A.H. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat. Disord. 2001, 8:95-100.
128. Rockenstein E., et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
129. Rommelfanger K.S., et al. Reduced MPTP toxicity in noradrenaline transporter knockout mice. J. Neurochem. 2004, 91:1116-1124.
130. Rosland J.H., et al. Acute and long term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice. Pharmacol. Toxicol. 1992, 70:31-37.
131. Ross G.W., et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov. Disord. 2006, 21:2062-2067.
132. Ross G.W., et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 2008, 63:167-173.
133. Salin P., et al. Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci. 1996, 8:1746-1757.
134. Santiago R.M., et al. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1104-1114.
135. Savica R., et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
136. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 1990, 519:122-128.
137. Schneider J.S., Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995, 4:245-255.
138. Schrag A. Psychiatric aspects of Parkinson's disease-an update. J. Neurol. 2004, 251:795-804.
139. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996, 50:275-331.
140. Shen W.B., et al. Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann. Neurol. 2010, 68:70-80.
141. Shin J.H., et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
142. Shulman L.M., et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:193-197.
143. Shulman J.M., et al. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6:193-222.
144. Slovin H., et al. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys. J. Neurophysiol. 1999, 81:858-874.
145. Sotiriou E., et al. Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol. Aging 2010, 31:2103-2114.
146. Spillantini M.G., et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
147. Sullivan K.L., et al. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:545.
148. Swainson R., et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
149. Tadaiesky M.T., et al. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
150. Takatsu H., et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 2000, 41:71-77.
151. Tanner C.M., et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119:866-872.
152. Taylor T.N., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
153. Thompson A.W., et al. Diagnostic accuracy and agreement across three depression assessment measures for Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:40-45.
154. Tillerson J.L., et al. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 2002, 178:80-90.
155. Torres E.S., et al. Mice overexpressing human alpha synuclein under the Thy1-promotor show increased fear conditioning and altered responses in anxiety related behavior. Soc. Neurosci. Abstr. 2010, 750.25:H18.
156. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5:107-110.
157. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 1971, 367:95-122.
158. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
159. van Vliet S.A., et al. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. Behav. Pharmacol. 2006, 17:453-462.
160. Vlaar A., et al. The treatment of early Parkinson's disease: levodopa rehabilitated. Pract. Neurol. 2011, 11:145-152.
161. Vuckovic M.G., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol. Dis. 2008, 32:319-327.
162. Waddington J.L. Effects of nomifensine and desipramine on the sequelae of intracerebrally-injected 6-OHDA and 5,6-DHT. Pharmacol. Biochem. Behav. 1980, 13:915-917.
163. Wakabayashi K., et al. Lewy bodies in the enteric nervous system in Parkinson's disease. Arch. Histol. Cytol. 1989, 52:191-194. (Suppl.).
164. Wang L., et al. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
165. Wang A., et al. Parkinson's disease risk from ambient exposure to pesticides. Eur. J. Epidemiol. 2011, 26:547-555.
166. Weintraub D., et al. Parkinson's disease-Part 3: neuropsychiatric symptoms. Am. J. Manag. Care 2008, 14:S59-S69.
167. Whitehead D.L., et al. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov. Disord. 2008, 23:1137-1145.
168. Wilson J.M., et al. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromolecular Med. 2002, 1:207-221.
169. Wolters E. Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S6-S12.
170. Yang W., et al. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum. Mol. Genet. 2007, 16:2900-2910.
171. Yi P.L., et al. Interleukin-1beta mediates sleep alteration in rats with rotenone-induced parkinsonism. Sleep 2007, 30:413-425.
172. Yoritaka A., et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2696-2701.
173. Zgaljardic D.J., et al. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J. Neural Transm. 2004, 111:1287-1301.
174. Zhou W., et al. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. J. Biol. Chem. 2008, 283:9863-9870.
175. Zhu C., et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 2004, 478:418-426.
176. Zhu X.R., et al. Non-motor behavioural impairments in parkin-deficient mice. Eur. J. Neurosci. 2007, 26:1902-1911.
177. Zhu H.C., et al. Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. J. Mol. Neurosci. 2011, (7 Jun, Electronic publication ahead of print).
178. Zuch C.L., et al. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J. Comp. Neurol. 2000, 427:440-454.